Pressure BioSciences Inc.’s (PBIO) Recently Acquired PreEMT™ Platform Enhances Development of Biotherapeutic Protein Drugs

May 30, 2018 13:43:32
  • Biologics offer novel ways of treating degenerative diseases like Alzheimer’s
  • Biologics are one of the fastest-growing drug categories
  • PreEMT™ technology improves quality, reduces cost of biologic manufacture

When we think of drugs, an image of potions in round-bottom flasks conjured up in labs comes to mind, or perhaps pills of one sort or another ingested with a sip of water, for about 90 percent of drugs currently in use have that profile. However, discovering that the human body will act as its own physician by dispensing protective proteins called antibodies to fight the toxins that bring on diseases has spurred efforts, naturally enough, to develop those proteins synthetically. This new class of biotherapeutic protein drugs, or biologics, tends to be more effective at combating pathological conditions with less side effects, since they mimic endogenously produced proteins, which target highly specific parts of the invader (antigens). Unfortunately, the production of biologics is easier said than done; it typically requires hundreds of process steps to assemble one of these complex biotherapeutic proteins. Therefore, it should come as no surprise that the PreEMT™ platform recently acquired by Pressure BioSciences Inc. (OTCQB: PBIO) is a welcome addition to biologic development.

The company recently announced the signing of an agreement with an international biopharmaceutical company to assess the potential of the PreEMT™ technology as the basis for a unique manufacturing process and as an enhancement to the quality of a key protein-based drug currently…

Read More>>

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office